Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Trial success for diabetic nerve therapy

01.06.2006


A potentially ground-breaking treatment for nerve damage caused by diabetes has shown promising results in preclinical and early patient trials.



The University of Manchester team has discovered that injection of a novel therapeutic that works by stimulating a person’s genes may prevent nerve damage – primarily to the hands and feet – caused by the disease.

The positive preclinical results – reported in the journal Diabetes – are further evidence that the research could lead to a new treatment for diabetic nerve damage or ’neuropathy’; initial-stage clinical trials on patients in the United States have also been encouraging.


Lead researcher Professor David Tomlinson says the study has massive potential for managing the condition and preventing thousands of foot amputations each year.

"The vast majority of non-traumatic hand and foot amputations carried out in UK hospitals are caused by diabetes and there are currently no treatments available to prevent or slow the progress of nerve disease in diabetic patients," he said.

"Our tests have shown that a single injection of a DNA-binding protein protected nerve function, stimulated nerve growth and prevented tissue damage that in humans can lead to limb loss."

An estimated 50 per cent of patients with long-term diabetes develop some form of neuropathy that can cause numbness and sometimes pain and weakness in the hands, arms, feet and legs. Progression to amputation is not inevitable, but it is always a threat.

Problems may also occur in other organs, including the heart, kidneys, sex organs, eyes and digestive tract.

"Diabetic neuropathy is a major problem in insulin-dependent diabetes, particularly in patients who have had the disease for a period of time," said Professor Tomlinson, who is based in the University’s Faculty of Life Sciences.

"Our approach to gene therapy is quite different to previous attempts at treatment: we use a DNA-binding protein called ZFP TFTM to poke life into the patient’s own genes and produce a growth factor that has a role in nerve protection and regeneration.

"As the data in the paper demonstrate, we have had some striking success."

The US clinical trials – carried out by Professor Tomlinson’s collaborators at biotech firm Sangamo BioSciences Inc – have also been encouraging with the only adverse event reported being mild injection-site reaction in four of the 12 diabetic patients tested, all of which resolved quickly.

"We are delighted by the progress of our clinical programme in diabetic neuropathy and by the reception it has received from the medical and scientific community," said Edward Lanphier, Sangamo’s President and CEO.

"We believe our DNA-binding protein may provide a novel and much-needed therapeutic approach to diabetic neuropathy and optimistically look forward to the next stage of development of this novel therapeutic when phase-two clinical trials start later this year."

The incidence of diabetes, a condition in which the amount of glucose in the blood is too high, is increasing dramatically with the World Health Organisation estimating that some 300 million people worldwide could be affected by 2025.

The causes of diabetic neuropathy are not fully understood but researchers investigating the effect of glucose on nerves believe it is likely to be a combination of factors.

Aeron Haworth | EurekAlert!
Further information:
http://www.manchester.ac.uk

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>